Gilead Sciences, Inc. — Wall Street Analyst Estimates & Price Targets

GILD

NASDAQHealthcareDrug Manufacturers - GeneralCIK 0000882095gilead.comAbout GILD

Last close · Oct 16, 2026156.19−1.18 (−0.75%)

Market cap$193.7B

7 firms' latest targets, last 90 days: median $158.00 ($126.00–$175.00), 1% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker

Each firm's latest target

last 90 days · 7 firms

Date	Firm	Target	Previous	Change	Vs price then	Vs price now
2026-10-12	Raymond James	$164.00	—	—	+8%	+5%
2026-10-08	RBC Capital	$126.00	$123.00	▲ 2%	-13%	-19%
2026-10-07	Truist	$158.00	$150.00	▲ 5%	+7%	+1%
2026-09-10	HSBC	$175.00	$155.00	▲ 13%	+20%	+12%
2026-07-29	Barclays	$145.00	$155.00	▼ 6%	+8%	-7%
2026-07-27	Morgan Stanley	$165.00	$166.00	▼ 1%	+26%	+6%
2026-07-20	Leerink Partners	$127.00	—	—	-5%	-19%

Consensus estimates

revenue and EPS by fiscal year · reported years marked

FY	Revenue	YoY	EPS	YoY	Revenue range	EPS range	Analysts
2023reported	$27.1B	-1%	$4.50	+24%	est. $27.1B+0%	est. $6.75	18
2024reported	$28.8B	+6%	$0.38	-92%	est. $28.3B+2%	est. $4.41	18
2025reported	$29.4B	+2%	$6.78	+1684%	est. $29.2B+1%	est. $8.11	18
2026	$30.7B	+4%	-$0.41	-105%	$30.5B–$31.0B	-$0.57–-$0.27	19
2027	$32.9B	+7%	$9.99	—	$31.8B–$33.5B	$9.44–$11.53	17
2028	$34.6B	+5%	$10.78	+8%	$32.2B–$37.6B	$9.15–$12.24	21
2029	$37.1B	+7%	$12.16	+13%	$36.1B–$38.2B	$11.72–$12.62	10
2030	$39.2B	+6%	$13.21	+9%	$38.1B–$40.4B	$12.73–$13.71	10

A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

The analysts at a glance

$158.00median target, 1% above the last close

Firms with a target · last 90 days: 7
Lowest – highest target: $126.00 – $175.00
Current grades of 15 firms: positive / neutral / negative: 12 / 3 / 0
Upgrades / downgrades · 12 months: 2 / 1
Consensus revenue growth · next 3 FY: +6% a year

Current grades

each firm's latest · 15 firms

As of	Firm	Grade
2026-10-08	Cantor Fitzgerald	“Overweight”
2026-10-08	RBC Capital	“Sector Perform”
2026-10-07	Truist	“Buy”
2026-10-07	J.P. Morgan	“Overweight”
2026-10-07	Morgan Stanley	“Overweight”
2026-09-10	HSBC	“Buy”
2026-08-05	Needham	“Buy”
2026-07-29	Barclays	“Equal Weight”
2026-07-21	Leerink Partners	“Market Perform”
2026-05-20	Maxim Group	“Buy”

5 more

2026-04-13	Citigroup	“Buy”
2026-02-11	Wells Fargo	“Overweight”
2026-02-11	Scotiabank	“Sector Outperform”
2026-01-26	UBS	“Buy”
2025-10-23	TD Cowen	“Buy”

Grade changes

last 24 months · 9

Date	Firm	Grade
2026-07-21	Leerink Partners	“Outperform” → “Market Perform” downgrade
2026-07-06	HSBC	“Hold” → “Buy” upgrade
2026-05-20	Maxim Group	“Hold” → “Buy” upgrade
2025-08-08	Truist	“Hold” → “Buy” upgrade
2025-07-25	Needham	“Hold” → “Buy” upgrade
2025-02-18	Deutsche Bank	“Hold” → “Buy” upgrade
2025-01-10	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2024-11-08	Maxim Group	“Buy” → “Hold” downgrade
2024-10-21	Leerink Partners	“Market Perform” → “Outperform” upgrade

51 older than 24 months

2024-10-07	Wells Fargo	“Equal Weight” → “Overweight” upgrade
2024-07-08	Raymond James	“Market Perform” → “Outperform” upgrade
2024-04-24	HSBC	“Reduce” → “Hold” upgrade
2024-02-22	Truist	“Buy” → “Hold” downgrade
2023-09-08	Bank of America	“Neutral” → “Buy” upgrade
2023-05-16	BMO Capital	“Market Perform” → “Outperform” upgrade
2023-04-25	RBC Capital	“Sector Perform” → “Perform” revised
2023-01-03	RBC Capital	“Outperform” → “Sector Perform” downgrade
2022-10-31	Barclays	“Underweight” → “Equal Weight” upgrade
2022-10-28	Truist	“Hold” → “Buy” upgrade
2022-10-28	Piper Sandler	“Neutral” → “Overweight” upgrade
2022-10-04	J.P. Morgan	“Neutral” → “Overweight” upgrade
2022-05-23	Leerink Partners	“Market Perform” → “Perform” revised
2022-02-28	BMO Capital	“Outperform” → “Market Perform” downgrade
2022-01-28	Argus Research	“Hold” → “Buy” upgrade
2022-01-06	Morgan Stanley	“Overweight” → “Equal Weight” downgrade
2021-04-01	Bernstein	“Market Perform” → “Outperform” upgrade
2021-03-30	Rothschild & Co Redburn	“Neutral” → “Buy” upgrade
2021-01-19	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2020-11-05	Wells Fargo	“Overweight” → “Equal Weight” downgrade
2020-09-15	Maxim Group	“Hold” → “Buy” upgrade
2020-07-20	Credit Suisse	“Underperform” → “Neutral” upgrade
2020-05-26	Truist	“Sell” → “Hold” upgrade
2020-05-01	Truist	“Hold” → “Sell” downgrade
2020-05-01	Raymond James	“Outperform” → “Market Perform” downgrade
2020-05-01	J.P. Morgan	“Overweight” → “Neutral” downgrade
2020-04-27	UBS	“Buy” → “Neutral” downgrade
2020-04-20	BMO Capital	“Outperform” → “Market Perform” downgrade
2020-04-20	Wells Fargo	“Overweight” → “Equal Weight” downgrade
2020-04-17	CFRA	“Hold” → “Sell” downgrade
2020-04-16	Baird	“Neutral” → “Outperform” upgrade
2020-03-20	Piper Sandler	“Neutral” → “Overweight” upgrade
2020-03-18	DZ Bank	“Hold” → “Buy” upgrade
2020-03-09	RBC Capital	“Top Pick” → “Outperform” downgrade
2020-02-28	DZ Bank	“Buy” → “Hold” downgrade
2020-02-06	Bernstein	“Outperform” → “Market Perform” downgrade
2020-02-05	Raymond James	“Strong Buy” → “Outperform” downgrade
2020-01-21	Guggenheim	“Buy” → “Neutral” downgrade
2019-12-13	Credit Suisse	“Neutral” → “Underperform” downgrade
2019-10-25	Maxim Group	“Buy” → “Hold” downgrade
2019-07-29	RBC Capital	“Outperform” → “Top Pick” upgrade
2019-07-15	Wells Fargo	“Market Perform” → “Outperform” upgrade
2019-05-28	Goldman Sachs	“Neutral” → “Sell” downgrade
2019-05-23	Citigroup	“Neutral” → “Buy” upgrade
2019-04-16	Longbow Research	“Buy” → “Neutral” downgrade
2019-04-10	UBS	“Neutral” → “Buy” upgrade
2019-02-12	Citigroup	“Buy” → “Neutral” downgrade
2019-02-12	Wells Fargo	“Outperform” → “Market Perform” downgrade
2019-01-03	Oppenheimer	“Perform” → “Outperform” upgrade
2018-10-26	Piper Sandler	“Overweight” → “Neutral” downgrade
2018-07-26	Baird	“Outperform” → “Neutral” downgrade

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.